Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$37.55
−$0.30 · -0.79%
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
Previous close
$37.55
−$0.30 · -0.79%
After-hours
$37.55
$0.00 · 0.00%
Sep 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
Day range
Current $37.55
52-week range
Current $37.55
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
79
Undervalued
Sentiment
69
Bullish
Risk
44
Elevated Risk
Momentum
46
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
Day range
Current $37.55
52-week range
Current $37.55
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 272.3M USD | 199.61M USD | 130.19M USD | 88.6M USD | 72.48M USD |
| Cost of goods sold | 67.93M USD | 49.25M USD | 39.64M USD | 25.38M USD | 18.21M USD |
| Gross profit | 204.37M USD | 150.37M USD | 90.55M USD | 63.21M USD | 54.26M USD |
| Research and development | 12.85M USD | 12.23M USD | 6.65M USD | 3.05M USD | 11.08M USD |
| Selling, general, and administrative | 152.91M USD | — | — | — | 39.82M USD |
| Operating expenses | 165.76M USD | 141.55M USD | 90.12M USD | 61.29M USD | 52.65M USD |
| Interest expense | 24.18M USD | 22.79M USD | 21.32M USD | 7.24M USD | 5.44M USD |
| Depreciation and amortization | 18.91M USD | 13.05M USD | 11.14M USD | 2.83M USD | 1.74M USD |
| Operating income | 38.61M USD | 8.82M USD | 431K USD | 1.92M USD | 1.61M USD |
| Net income | −5.14M USD | −17.48M USD | −24.41M USD | −14.09M USD | −18.01M USD |
Company facts updated Sep 10, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Feb 8, 2013 | 1:5 | — | — |
Stock split | Feb 24, 2012 | 1:8 | — | — |
Stock split | Sep 28, 2007 | 231:500 | — | — |
Effective Feb 8, 2013
1:5
Effective Feb 24, 2012
1:8
Effective Sep 28, 2007
231:500
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI38.83M0.00%2.3T USD0.03%$375.56-0.54%
iShares Russell 2000 ETFIWM31.71M0.04%80.51B USD0.19%$290.64-1.37%
Vanguard Extended Market ETFVXF14.81M0.02%93.7B USD0.05%$238.67-1.11%
iShares Russell 2000 Growth ETFIWO11.38M0.08%14.7B USD0.24%$370.95-1.63%
State Street SPDR S&P Pharmaceuticals ETFXPH10.17M1.65%616.33M USD0.35%$69.32-1.51%
Vanguard Russell 2000 ETFVTWO7.04M0.04%17.4B USD0.06%$117.51-1.37%
Schwab U.S. Small-Cap ETFSCHA5.93M0.03%22.86B USD0.03%$34.10-1.04%
U.S. Micro Cap Portfolio ETFDFMC4.77M0.06%7.82B USD0.43%$59.20-1.12%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAU.S. Micro Cap Portfolio ETFDFMCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
